COMPASS Pathways alternatives

Several biotech firms advance psilocybin or related compounds with pipelines targeting anxiety, addiction or depression subtypes. Differences often appear in study size, combination with antidepressants, or emphasis on digital support tools versus COMPASS's large TRD-focused program.

COMPASS completed one of the largest randomised psilocybin studies in TRD. Rivals may run smaller Phase 2 trials or broader multi-indication programs, affecting speed to potential approval and data robustness for regulatory review.

Some alternatives pair compounds with proprietary apps or remote monitoring platforms more extensively. COMPASS incorporates digital elements but centres primarily on drug development and in-person therapy models.

A few firms explore overlapping indications though most prioritise depression or substance use. Direct comparisons depend on published protocols and whether they match COMPASS's focus on evidence-based psilocybin formulations.

As pre-commercial biotechs, most follow similar investigational paths with future pricing unknown. Differences may emerge in trial access, expanded access programs, or eventual therapy delivery costs once approved.

Review published trial results, indication match, therapy protocol requirements, and geographic trial availability. COMPASS emphasises large controlled studies while alternatives may offer earlier access or different compound profiles.